2021年7月,《癌症发现》期刊发布了题为“A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab”的文章,报道了一...
3) 经组织学或细胞学证实的晚期 Mesothelin 表达阳性恶性实体瘤受试者(不接受肉瘤 样间皮瘤或双相型间皮瘤); 3.1)剂量递增阶段:无标准治疗方案,或经标准方案治疗失败或复发,或不耐 受标准治疗方案,或现阶段不适用标准治疗方案; 3.2)剂量扩展阶段:不可切除的经一线治疗进展或复发或存在远处转移; 4) 所有受试者...
Chimeric antigen receptor (CAR)-T cell therapy holds promise, but its efficacy is hindered by tumor antigen escape and heterogeneity. To address these challenges, we developed a novel bispecific T cell engagers CAR-T (BiTEs CAR-T) targeting Mesothelin (MSLN) and secreting NKG2D-Bispecific T ...
Our findings indicate the promise of anti-Mesothelin CAR-NK cells as a potential treatment option against cervical cancer, as well as other Mesothelin malignancies.Kutle, IvanaPolten, RobertStalp, Jan LennartHachenberg, JensTodzey, FelixHass, Ralf...
国际知名杂志《Journal of Hematology & Oncology》刊登了我国医学研究者们的一项成功改造CAR-T技术的临床研究,研究中提及的CAR-T产品选择的靶点有mesothelin(MSLN,又称为间皮素,可以应用于多种上皮癌症,比如恶性间皮瘤、胰腺癌、胃癌、卵巢癌等)。 其中1例晚期胰腺癌患者,接受的是静脉回输的CAR-T治疗,治疗后全身...
6 Mesothelin (MSLN) is a 40-kDa membrane protein attached to the cell surface by phosphatidylinositol and is reportedly expressed by solid tumors.7, 8, 9, 10 A recent study used MSLN to target various solid cancers;9, 10, 11 however, the use of modified MSLN-CAR-T cells to treat ...
摘要:目的分析CEA、EGFR等肿瘤相关抗原作为CAR-T治疗靶点在结直肠癌中的分布。方法回顾并选取2014年-2017年的122例结直肠癌病例,应用免疫组织化学法检测肿瘤相关抗原CEA、EGFR、HER2、Mesothelin、MUC1和EpCAM在结直肠癌组织中蛋白表达范围和强度。结果除HER2(37.5%)外,其它肿瘤相关抗原在结直肠癌中表达阳性率均在50...
联合免疫,安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用 1文献来源Adusumilli PS,Zauderer MG,Rivière I,et al.A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients wi...
An of the article "Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity" by P. S. Ad... Villanueva,Tesi - 《Nature Reviews Cancer》 被引量: 1发表: 2014年 Control of human mesothelin-expressing tumors by DNA vaccines. Mes...
Single-cell RNA-Seq reveals thepotential risk of anti-mesothelinCAR T Cell therapy toxicity todifferent organs in humansLu Wen 1 † , Yu Huang 1 † , Ling Peng 1 † , Kaiping Zhao 2 , Yan Sun 3 ,Zhicai Lin 3 , Yuanyuan Chen 3 , Zhong Li 3 , Qijun Qian 3,4 ,Fan Tong ...